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Abstract 
Follicle-stimulating hormone (FSH) is involved in the regulation and maintenance of vital 
reproductive processes, such as gametogenesis, follicular development and ovulation. Produced 
in the anterior pituitary, FSH is a glycoprotein hormone that exists as a family of isohormones. 
Follicle-stimulating hormone concentrations have traditionally been measured by 
radioimmunoassay (RIA). However, results generated using RIA are a determination of the 
immunological activity of FSH. The potential of FSH to generate a biological response cannot be 
measured by RIA. Therefore, the identification of physiologically significant differences in the 
activity of these isoforms requires the use of assay systems that can differentiate between the 
biological activity of the FSH isoforms. 
Commonly used assays for measuring the biological activity of FSH are based on the 
measurement of aromatase activity in cultured rat Sertoli cells following stimulation with FSH. 
However, these assays have an inherently high ethical cost involved due to the use of primary 
tissue culture. In addition, the variation in these assays associated with differences between 
animals is difficult to eliminate. Recently a bioassay for human FSH has been described based on 
FSH stimulation of cyclic AMP production by a Chinese hamster ovary (CHO) cell line stably 
expressing the human FSH receptor (FSH-R). The purpose of this study was to evaluate the 
potential usefulness of this CHO FSH-R cell line expressing the human receptor for FSH to be 
used as a bioassay to measure the biological activity of ovine FSH. The receptor cell line bioassay 
described in this study is based on the ability of FSH to stimulate cAMP production by cultured 
CHO FSH-R cells. Optimisation of the culture system to enable the bioactivity of ovine FSH to 
be measured by bioassay was undertaken. This involved optimising the density of cultured cells, 
the time in culture and time exposed to FSH and the most suitable dose range for FSH. The 
influence of matrix effects, such as those exerted by serum was also investigated. The specificity 
of the assay towards FSH was also determined as was the sensitivity, accuracy and precision of 
the assay. No stimulation of cAMP production was seen in CHO FSH-R cells following treatment 
with a-FSH, ~-:-FSH, LH, TSH, GH, prolactin or vasopressin at concentrations up to 10 µg/ml. 
Although the methodology used differed sl ightly depending on the presence or absence of serum, 
all assayed were performed using the following methods and materials. Freshly thawed FSH-R 
cells were bulked up in culture, and aliquots of 1 x 105 to 5 x 105 cells/well dispensed into 48 well 
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culture dishes and incubated overnight at 37°C. The assay culture media was then replaced with 
0.25 ml fresh media (cx-MEM + 0.1 % BSA+ 0.25 mM 3-isobutyl-1-methyl-xanthine) containing 
varying doses of NIH-FSH-RP2 (RP2) FSH preparations or FSH containing samples, and the 
cells incubated for 4 hours at 3 7°C. The assay culture media was then removed and stored frozen 
at -20°C until assayed for cyclic adenosine monophosphate ( cAMP) by RIA. 
On~e optimal assay conditions were determined, the CHO FSH-R cell bioassay was used to 
measure FSH concentrations in ovine serum, pituitary extracts and medium from cultures of 
ovine pituitary cells. It was found that the concentrations of FSH in serum from intact sheep was 
close to the detection limit of the assay. Thus, while FSH concentrations could be measured in 
serum from some sheep, other animals had concentrations that were too low to be accurately 
measured by the bioassay in its present form. The assay was, however, well suited to measuring 
FSH concentrations in serum from sheep that had elevated concentrations of FSH. In one study, 
FSH concentrations measured by the bioassay were compared to those measured by RIA in sheep 
that had been ovariectomised and then hypophysectomised. It was found that the profile of FSH 
concentrations following hypophysectomy was similar whether measured by RIA or by bioassay 
(R2=0.7513), though absolute concentrations sometimes differed. This suggested that the 
immunoassay and bioassay were not always measuring the same characteristics of FSH. The 
assay was also used to measure FSH concentrations in samples of ovine hypophyseal venous 
blood. However, the results obtained for these samples indicated a poor correlation between FSH 
concentrations obtained by bioassay and RIA. Levels of bioactive FSH in hypophyseal venous 
blood fluctuated markedly and were up to 10-fold higher than the associated RIA concentrations. 
The CHO-cell bioassay was also found to be very suitable for measuring pituitary concentrations 
of FSH. In one study, pituitary extracts underwent chromatography and the separated isoforms of 
FSH were analysed by bioassay and RIA. Again, there was excellent correlation (R2=0.9328) 
between the concentrations of FSH measured both assay types. However, some differences were 
apparent suggesting a discrepancy in the biological and immunological characteristics of different 
FSH isoforms. The bioassay was also used to measure FSH concentrations in media from 
pituitary cells in tissue culture where serially diluted samples displayed good parallelism with the 
RP2 FSH standard curve. 
Results of this study demonstrate that the CHO FSH-R cell bioassay is suitable for measuring the 
biological activity of ovine FSH in a variety of biological fluids. The use of a permanent cell line 
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eliminates the high ethical cost associated with primary tissue culture that other bioassay systems 
have. The inherent variation associated with culture systems utilising tissue from different 
sources is also avoided. The sensitivity of the bioassay is suitable for measuring FSH in 
surgically altered sheep or hypophyseal blood concentrations where FSH levels are generally 
higher than those in the peripheral circulation. In addition to blood samples, the bioassay is also 
excellent for monitoring FSH activity in pituitary extracts and in media from tissue culture. 
However, the sensitivity of the bioassay currently does not always allow measurement of 
bioactive FSH concentrations in serum samples with low FSH levels. 
In summary, the CHO FSH-R cell bioassay described in this study offers a useful alternative to 
RIA and other bioassays for monitoring the biological activity of ovine FSH and its isoforms in 
various biological fluids. It is concluded that this convenient and robust bioassay may have . 
considerable application in future investigations of ovine FSH bioactivity. 
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Chapter One· 
INTRODUCTION 
2 
1 Introduction 
Follicle-stimulating hormone (FSH) is a key glycoprotein hormone involved in the regulation and 
maintenance of essential reproductive processes, including gametogenesis, follicular development 
and ovulation (Scaramuzzi et al, 1993; Linsay, 1991) and acts by binding to specific receptors 
localized in the gonads. In the male, FSH acts on the Sertoli cells in the seminiferous tubules of 
the testis, to stimulate spermatogenesis. However, the mechanisms of FSH stimulation of 
spermatogenesis remains unclear. The target for FSH action in the female are the granulosa cells 
of follicles, where it stimulates production of estrogens and progestins, as well as various 
nonsteroidal substances (Dahl and Hsueh, 1988). 
1.1 Structure of FSH 
The two pituitary gonadotrophins, FSH and luteinizing hormone (LH) are members of the 
glycoprotein protein hormone family, which also include pituitary thyroid stimulating hormone 
(TSH), and the placental gonadotrophin chorionic gonadotrophin (CG), found only in equids and 
primates. All glycoprotein hormones are composed of a common a -subunit that is noncovalently 
associated with a hormone-specific (3-subunit. In addition, all the glycoprotein hormones consist 
of a mixture of molecular isoforms. The nature of the microheterogeneity of glycoprotein 
hormones arise from differences in glycosylation of the hormones, including the degree of 
terminal sialylation and/or sulfation (Ulloa-Aguirre et al, 1995). The resulting acidic-base charge 
provides the major basis for separation by chromatographic techniques, such as isoelectric 
focusing or chromatofocusing (Simoni et al, 1994). Therefore, oligosaccharide chains of varying 
stages of completion, and different oligosaccharide structures are found on a single 
gonadotrophin. Although the heterogeneity of FSH is well established, regulation of FSH 
heterogeneity in the circulation is poorly understood. In addition, the functional significance of 
such a variety of isoforms for FSH remains unclear. Structural differences in these isoforms alter 
a number of physical and physiological properties of the hormone, including changes in receptor-
binding activity, plasma half-life, and in vivo and in vitro bioactivity. Therefore a mixture of 
circulating FSH isoforms reaches target tissues within the gonads to influence a variety of 
physiological endpoints. 
1.1.1 Glycosylation 
Unlike other hormones now known to be glycoproteins, in which a single protein chain is 
glycosylated, both the a- and ~-subunits of the glycoprotein hormones, including FSH, are 
glycosylated. For the a subunit of FSH (92-96 amino acids in length), the pattern of 
glycosylation is very consistent, with two N-linked glycosylation sites at asparagine (Asn) 52 or 
56 and Asn78 or 82. Patterns of glycosylation on the ~-subunit, however, are more variable than 
those found on the a-subunit. The ~-subunit, comprised of 111-112 amino acids, exhibits two 
glycosylation sites at Asn6, 7, or 13 and Asn23, 24, or 30 (Ulloa-Aguire et al, 1995). 
Glycosylation and the processing of incorporated oligosaccharides involves a complex 
biosynthetic pathway that begins in the rough endoplasmic reticulum, and continues through the 
Golgi apparatus until the mature hormone is transported to secretory granules. The numerous 
carbohydrate intermediates resulting from processing in the Golgi apparatus are responsible for 
many of the FSH glycoforms secreted by the pituitary. 
The oligosaccharide structures on FSH are highly variable and play a key role in determining the 
biological properties of the hormone. Most oligosaccharide chains in FSH are double branching 
structures with one end terminating in a negatively charged group (GalNAc-S04 or Gal-sialic 
acid) and the other branch terminating in either a negatively charged group or in non-charged 
mannose (Ulloa-Aguire et al, 1995). Tribranched oligosaccharides of different types containing 
sialic acid residues are also found. The main chemical basis for the isoform differences and 
extensive charge heterogeneity of FSH is attributed to variations in the structure and distribution 
of sialylated oligosaccharides. Follicle-stimulating hormone, in general, is rather acidic (Simoni 
et al, 1994), with a median isoelectric point (pl) approximately 4-5. Enzymatic desialylation of 
ovine pituitary FSH results in a redistribution of the isohormones towards less acidic forms (Keel 
and Schanbacher, 1988). Isoforms of FSH identified by charge-based fractionation differ from 
each other not only with respect to the degree of terminal sialylation and sulphation, but also in 
the inner carbohydrate moieties of the oligosaccharide side chains. Therefore, many FSH 
isoforms may have the same charge yet differ in oligosaccharide composition. 
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1.1.2 FSH lsoform Distribution 
Although the factors affecting final gonadotrophin isoform distribution are complex and 
multifactorial, endocrine changes clearly regulate the proportions of FSH isoforms both within 
the pituitary and in the peripheral circulation. Differences in circulating FSH iosforms may be 
mediated by a number of different factors such as: 1) regulated preferential secretion of one or 
more FSH isoforms; 2) differences in the removal of carbohydrate moieties from the FSH 
molecule by circulating enzymes; and 3) changes in metabolic clearance (Ulloa-Aguire et al, 
1995). 
1.2 Synthesis and Release of FSH 
Follicle stimulating hormone is the primary hormone involved in the emergence of waves of 
follicles, and its decline is associated with selection of a dominant follicle. The dominant follicle 
then becomes dependent on LH for further development when concentrations of FSH are 
minimal. The patterns of secretion of the two gonadotrophins are highly divergent, yet they can 
be produced in the same cell under the control of a single releasing hormone. The synthesized 
gonadotrophins are stored in secretary granules within the cytoplasm, and are secreted by 
exocytosis (Roche, 1996). 
In the pituitary, the major hormone responsible for stimulating gonadotrophin release is 
gonadotrophin-releasing hormone (GnRH). Specific receptors on gonadotrophs respond to 
GnRH, triggering the release of intracellular Ca2+, causing a transient release of both FSH and 
LH. The gonadotrophs become insensitive to GnRH, therefore the pulsatile nature of its release 
is necessary to prevent down regulation of its receptors. Without continual pulsatile stimulation 
by GnRH, secretion of LH and FSH declines rapidly, as do concentrations of messenger RN As 
for the subunits of gonadotrophins in the anterior pituitary gland. 
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Other hormones that influence the secretion of FSH include estradiol, progesterone, inhibin; and 
activin. lnhibin and estradiol act directly at the anterior pituitary to decrease expression of the 
gene encoding the FSH subunit by reducing both the transcription and stability of mRNA, thereby 
negating the GnRH effects on FSH release. Estradiol causes a major decrease in FSH, while LH 
is initially decreased and then increased. lnhibin also suppresses FSH release, but without 
affecting LH. A summary of factors that influence FSH secretion is shown in Figure 1.1 
• 
Estradiol 
GnRH 
Activin 
Fig 1.1 Schematic representation of factors known to regulate synthesis and secretion of 
FSH. Binding of GnRH to its receptors stimulates both protein kinase C (PKc) and 
protein kinase A (PKA) second messenger systems, thereby activating the stimulatory G 
protein (05). This, in tum, leads to the activation of the genes encoding a.- (not pictured) 
and ~- FSH subunits. Inhibin likely binds with an inhibitory G protein (G;) coupled 
receptor. This may lead to inhibition of the stimulatory activity of GnRH and activin on 
FSH synthesis and secretion. Interaction of estradiol with its receptor inhibits 
transcription of the gene for ~-FSH subunit. However, activation of the estradiol receptor 
leads to an increase in transcription for the gene encoding the receptor for GnRH (not 
shown) (Nett, 1990). 
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1.3 Physiology of FSH 
In the female1 the primary role of gonadotrophins is to initiate and sustain follicular functions. 
The initial stages of folliculogenesis occur independently of gonadotrophic hormones. In the 
adult ovary, folliculogenesis starts when follicles leave the pool of resting follicles to enter the 
growth phase. From there, the development of the follicle is characterized by a dramatic course 
of cellular proliferation and differentiation. 
1.3.1 Follicular Development 
Follicles in the ovary begin to form during fetal development and most remain in a resting stage 
until they either degenerate or are activated by various signals to enter the growth phase. These 
follicles constitute the stock of the resting follicles . Three types of resting follicles (primordial, 
intermediary, small primary) are evident in most mammals and can be distinguished by the size of 
the follicle and the structure and number of the granulosa cells surrounding the oocyte. With 
increasing age, the population of resting follicles progressively decreases. The age-related 
depletion of the resting follicle stock occurs as a result of two processes: atresia and entry into the 
growth phase. In sheep, the first follicles begin development at day 70 of gestation and by birth, 
at day 148, antral follicles are well developed. In adult ewes the estimated growth time for 
follicles is six months. Formation of the antrum occurs in ovine follicles when they reach 0.2mm 
in diameter and further increase in follicle size is attributed to an increase in granulosa cell 
numbers and a build up of follicular fluid. The granulosa cells reach a maximum growth rate 
when the follicle is approximately 1.0mm in diameter, after which the number of cell divisions 
declines until there is almost no mitotic activity in the mature preovulatory follicle. The follicular 
fluid is a derived from serum and is enriched with secretory products from follicle cells such as 
glycosaminoglycans, insulin-like growth factor I (IGF-1), inhibin, transforming growth factor~ 
(TGF~), prostaglandins and steroids. These substances may amplify or inhibit the actions of 
gonadotrophins such as LH and FSH. 
Models of follicular growth and development based primarily on follicle size, number and 
morphological characteristics have been superseded by those based more on the functional 
capacities of the functional cells of the follicle . In one such model (Scaramuzzi et al, 1993), 
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follicles can be quiescent (i.e. primordial), committed to growth, ovulatory or atretic. Committed 
follicles can be non-responsive to gonadotrophins, and those that are responsive can be 
independent of or dependent on FSH and LH. 
The role of gonadotrophins in initiating follicular growth is unclear. However, at advanced stages 
of follicular growth, antral follicles become dependent on FSH support for terminal follicular 
growth, leading to the emergence of waves of follicles. At this stage, an inappropriate 
stimulation, particularly by LH, can cause atresia. (Findlay, 1994 ). The decline of FSH is 
associated with selection of a dominant follicle that becomes dependent on LH for ovulation 
when concentrations of FSH are minimal. In addition, the reinitiation of growth in primordial 
follicles and acquisition of responsiveness of granulosa cells to FSH can occur independently of 
gonadotrophin support, indicating a role of autocrine and paracrine factors in folliculogenesis 
In this model, the follicles committed to growth can be differentiated along a hierarchy according 
to their developmental status. Granulosa cells clearly undergo differentiation as the committed 
follicle move through the functional stages towards ovulation or atresia (Findlay, 1994). The 
stages of differentiation can be determined using parameters such as expression of gonadotrophin 
receptors, production of cyclic adenosine monophosphate ( cAMP) in response to secretagogues, 
and production of steroids ( estradiol, progesterone and 20a-hydroxyprogesterone) and peptide 
hormones (inhibin, oxytocin). Relatively undifferentiated granulosa cells, found in early 
committed follicles, lack any significant differentiation in terms of ability to respond to FSH and 
LH and to produce steroids and peptides (Scaramuzzi et al, 1993). Granulosa cells of small-
medium bovine follicles demonstrate responsiveness to FSH and LH, but will not spontaneously 
luteinize in vitro unless treated with gonadotrophin. However, fully differentiated granulosa cells 
found in ovulatory follicles are generally capable of spontaneous luteinization in vitro (Findlay, 
1994). 
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1.3.2 Control and Regulation of Folliculogenesis 
The initiation of follicular growth is still not fully understood and there are two schools of 
thought on whether the initial stimulus for growth comes from the oocyte or the granulosa cells. 
While FSH is thought to influence the number of follicles that commence growth, gonadotrophins 
may not be essential in initiating follicle growth as follicles with four or five layers of granulosa 
cells have been observed in sheep following hypophysectomy. Although it is uncertain whether 
preantral follicles require gonadotrophins for follicular growth, it is evident that growth related 
processes are slowed down in their absence (Peters and McNatty, 1980). 
1.3.2.1 Role of Estrogen in Follicles 
Follicle-stimulating hormone is thought to stimulate the differentiation of the granulosa cells and 
promote antrum formation. To prevent the follicle from undergoing atresia, continuous presence 
of FSH is required. In human and sheep, FSH is present in some, but not all antral follicles. In 
follicles which have a higher concentration of androgen than estrogen (androgenic follicles), FSH 
is not present in detectable amounts. These follicles always undergo atresia. 
Estrogen, primarily in the form of 17~-estradiol, is found in antral follicles arising mainiy from 
the theca and granulosa cells. In the sheep ovary, over 95% of estradiol produced originates from 
granulosa cells, while the output of estradiol from theca interna cells is negligibl (McNatty and 
Henderson, 1987). Estradiol in conjunction with FSH enhances mitotic activity and influences 
the number of LH and prolactin receptors on granulosa cells. The concentration of estradiol in 
some follicles can be as high as 40,000 times that of estradiol in plasma in sheep. The 
estradiol/androgen balance in the follicle is kept in favour of estradiol by synthesis of estradiol 
from androgen. This ability to metabolize androgen to estrogen is maintained by FSH, thus 
follicles deficient in FSH lose this ability and eventually become androgenic and degenerate. 
Follicles which have been FSH-estradiol primed can then respond to a preovulatory rise in LH 
which subsequently leads to ovulation and corpus luteum formation. 
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As a result of the elevated levels of circulating estrogen, FSH production from the pituitary falls 
resulting in lowered peripheral concentrations of FSH. Without exposure to sufficient levels of 
FSH, the smaller antral follicles are no longer able to maintain their levels of estrogens and 
consequently undergo atresia. Therefore the dominant follicle stimulates its own growth and 
simultaneously deprives the others of FSH, accelerating their demise. The remaining healthy 
follicles already have high level of estrogens stored and continue to accumulate FSH. 
Eventually the heightened level of circulating estrogen, secreted by the developing follicle, 
stimulates an increase in LH production, which accumulates in the follicle. Exposure of the 
follicle to high levels of LH initiates the final stages of oocyte maturation, inhibition of estrogen 
secretion and further granulosa cell divisions. Increased prostaglandin synthesis and initiation of 
the corpus luteum formation from the granulosa cells also occur due to the presence of LH. 
1.3.2.2 Activin and lnhibin in Follicles 
Inhibin, activin, and their binding protein, follistatin, have direct and indirect effects on granulosa 
and theca cells that can influence follicular development and steroidogenesis (Roche, 1996). 
Inhibin is a glycoprotein that has been isolated from follicular fluid as a heterodimer consisting of 
a common a-subunit combined with one of two ~-subunits, ~A (inhibin-A) or ~B (inhibin-B) 
(Gougeon, 1996). The ~A- and ~B-subunits combine to give three forms of activins: activin 
(~A~B), activin A (~A~A), and activin B (~B~B). Follistatin is a monomeric glycosylated 
protein that is the major high-affinity binding protein for both inhibin and activin in follicular 
fluid. 
A characteristic feature of activin and inhibin are the opposite effects that these peptides exert on 
certain follicular functions. On one hand, inhibin stimulates androgen production in theca intema 
cells, while activin exerts a negative influence on androgen production in the same cells. On the 
other hand, inhibin appears to be a potent inhibitor of ovarian cell proliferation in mice, whereas 
activin has been shown to stimulate in vitro proliferation of immature rat granulosa cells (Li et al, 
1995). The effects of follistatin on steroid synthesis by preovulatory granulosa cells are indirect. 
Follistatin inhibits the suppressive effects of activin, as it binds with high affinity to activin and 
with lower affinity to inhibin (Gougeon, 1996). 
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Activin has been shown to play an important role in regulating granulosa cell development and 
functional integrity in ovarian follicles. Receptors and mRNA for activin have been found in 
oocytes, granulosa cells and theca interna cells of the rat (Cameron et al, 1994 ). Activin 
increases the number of FSH receptors in rat granulosa cells and stimulates the reorganization of 
follicular structures from monolayer cultures of immature granulosa cells in both rats and humans 
(Li et al, 1995). Inhibin has both autocrine and paracrine effects; it increases LH-induced 
androgen synthesis in thecal cells, and production of inhibin is stimulated by steroids and FSH 
(Roche, 1996). Thus, inhibin and activin provide a mechanism by which follicles can 
communicate directly with the pituitary in a feedback relationship with FSH. Therefore, within 
individual follicles a sequential change of inhibin, activin and their binding proteins may 
ultimately determine the different fates of the follicles committed to growth. 
1.4 Biological Features of FSH lsoforms 
Due to structural differences, FSH isoforms differ in their ability to bind to target cell receptors, 
survive in the circulation, and stimulate a biological response in vitro and in viva. 
Removal of the carbohydrate moieties in FSH has been found to increase the receptor binding 
ability and immunological activities of the hormone in radioreceptor and radioimmunoassays 
(Manjunath et al, 1982). In contrast, the deglycosylated FSH molecules have a greatly 
diminished capacity for stimulation of cAMP by gonadal cells (Manjunath et al, 1982). In 
addition, when combined with intact FSH, the deglycosylated FSH has been shown to interfere 
with the ability of the intact hormone to elicit steroidogenesis and these hormones are potent and 
specific antagonists in in-vitro (Manjunath et al, 1982). 
The protein domain of the FSH molecule binds to specific plasma membrane FSH receptors, 
while the carbohydrate moieties of FSH are believed to interact with membrane components 
either within or adjacent to the receptor molecule. In general, certain peptide regions are thought 
to be critical for receptor binding, whereas the oligosaccharides are thought to be important for 
signal transduction. Indeed, receptor binding and signal transduction has been shown to be 
dissociable functions involving different sites on the FSH glycoprotein (Valove et al, 1994 ). 
Biologic Features 
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Biologic Features 
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Fig 1.2 Hormonal factors influencing the synthesis and release of different FSH isoforms 
from the pituitary gland and the distribution of these isoforms associated with various 
physiological conditions (Roche, 1996). 
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Studies comparing in vitro bioactivity with immunoreactivity appear to indicate that less acidic, 
less glycosylated FSH isoforms have a higher biopotency in vitro, but have a shorter half-life 
(Stanton et al, 1992). Although heterogeneity has been studied extensively in the pituitary, 
regulation of FSH heterogeneity in the circulation is poorly understood due in part to the 
relatively low concentrations of circulating FSH. Despite this limitation, studies examining the 
correlation between qualitative differences in pituitary FSH content with age, sex and stage of the 
estrous cycle indicate that endocrine changes clearly regulate the proportions of FSH isoforms 
both within the pituitary and in the peripheral circulation (Roche, 1996). A majority of studies 
show that estradiol is associated with increased release of less acidic isoforms of FSH, and 
androgens are associated with increased release of more acidic forms of FSH. The onset of 
GnRH induced puberty in sheep and the preovulatory phase in normal cycling women is 
accompanied by major shifts in the distribution pattern of circulating FSH isoforms, and an 
associated increase in FSH bioactivity (Padmanabhan et al, 1992). A summary of factors thought 
to influence the synthesis and distribution of different FSH isoforms is shown in Figure 1.2. 
1.5 FSH Mode of Action 
Follicle-stimulating hormone, like all protein hormones, mediates its effects on target cells via 
specific protein receptors located on the cell surface. Receptors for FSH have been studied in 
both males and females. The primary location for FSH receptors in males is the Sertoli cells 
within the seminiferous tubule. In females, the major site of FSH receptor expression is the 
granulosa cells. 
In both sexes, the secondary messenger cAMP mediates the action of FSH through its receptors. 
Treatment with membrane soluble cAMP analogs or cAMP-inducing agents stimulates multiple 
physiological responses in granulosa cells. Furthermore, the action of FSH in granulosa cells is 
enhanced with the addition of phosphodiesterase inhibitors that reduce cAMP breakdown (Welsh 
et al, 1985; Simoni et al, 1997). Follicle-stimulating hormone induced increase of intracellular 
cAMP in granulosa or Sertoli cells activate PKA, which results in subsequent phosphorylation of 
structural proteins, enzymes, and transcriptional activators. 
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Binding of FSH to its receptors in vitro is a process highly dependent on temperature and salt 
concentration and slowly becomes non-reversible at 37°C (van Loenen et al, 1994a). However, 
only a few minutes are required to attain steady state receptor activation, as measured by cAMP 
production in Sertoli cells, whereas the development of high-affinity receptor binding requires 
several hours (van Loenen et al, 1994b). The binding of FSH to granulosa cell membrane 
preparations is fully reversible only when hormone-receptor association occurs at 4°C and 
requires strong acidic treatment. The molecular basis for the slow formation of an irreversible 
interaction between FSH and its receptors is unknown. Whether the stabilization of FSH 
receptors occurs in vivo is also not known, although, in such a case, it could be an important step 
for hormone-receptor internalization. 
1.5.1 FSH Receptor Structure 
FSH receptors belong to the family of G protein-coupled receptors, characterized by complex 
transmembrane proteins consisting of seven hydrophobic helices inserted into the plasmalemma 
and by intracellular and extracellular domains of variable dimensions depending on the ligand 
(Simoni et al, 1997). Early experiments indicate that FSH receptors are oligomeric glycoproteins, 
consisting of four disulfide-linked monomers (Reichert and Dattatreyamurty, 1989). It is thought 
that FSH receptor binding is dependent on the integrity of the disulfide bonds, which stabilize the 
receptor conformation. The intracellular portion of FSH receptors is coupled to a G Protein and, 
upon receptor activation of the extracellular domain, initiates a cascade of events that ultimately 
leads to the specific biological effects of FSH in target tissues. 
Depending on the species, the calculated molecular mass of the mature receptor protein ranges 
between 75 and 76.5 kDa, based on the cDNA sequence (Simoni et al, 1997). Further 
characterization of the amino acid sequence and hydropathy plot analysis suggests that FSH 
receptors consist of a large hydrophilic domain followed by hydrophobic regions 21-24 amino 
acids long, which span the plasma membrane seven times. At the C terminus, the sequence 
predicts a highly basic cytosolic segment. 
Beside the transmembrane domain with the typical seven membrane-spanning helices, the 
glycoprotein hormone receptors are characterized by a very large extracellular domain in the N 
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terminus region, required for interaction with complex ligands. The extracellular domain displays 
several significant primary and secondary structural features. It is composed of several 
imperfectly replicated leucine-rich units of approximately 24 residues each, which, because of 
there amphiphatic character, are thought to mediate interaction between the hydrophilic hormone 
and the hydrophobic membrane (Gromoll et al, 1996). The secondary structure is determined by 
eight highly conserved cystein residues, a structural feature that can also be found in LH receptors 
and TSH receptors. This suggests a crucial role for the cystein residues in maintaining 
conformational (Gromoll et al, 1996). The extracellular domain of FSH receptors also has three 
potential sites for N-linked glycosylation conserved in all species at amino acid positions 191, 
199, and 293. Additional species specific glycosylation sites may also be present. Although it 
was suggested that the glycosylation pattern of FSH receptors may affect hormone binding, recent 
studies indicate that glycosylation is rather required for correct folding of the receptor protein and 
transportation to the membrane (Davis et al, 1995). 
1.5.2 Signal Transduction 
FSH stimulation of cAMP production involves three distinct plasma membrane components: the 
hormone receptor, the nucleotide regulatory or G protein (guanine nucleotide binding protein), 
and the catalytic moiety of adenylyl cyclase. The receptor and cyclase are responsible for 
hormone recognition and enzymatic activity, respectively, and the G protein, in the presence of 
GTP, modulates their activity. After interaction with the hormone, the receptor becomes coupled 
to the G protein. The FSH activated G protein, termed Gs, stimulates adenylyl cyclase activity 
and, in turn, production of cAMP (Zhang et al, 1991 ). Association of the receptor to Gs can only 
occur when the receptor is in an active state. This implies that the receptor exists in an 
equilibrium between two forms, inactive and active, the second resulting in a conformational 
change of the inactive form. A summary of events that take place following receptor binding and 
activation is detailed in Figure 1.3. The interaction between FSH and its receptor determines 
receptor isomerisation to the active form and initiates a cascade of events collectively indicated as 
signal transduction. 
FSH 
Ca2• 
Calcium channel 
cAMP 
Protein kinase A "80 
0/ ®-· o--6 
0~ 0 p 
I 
© 
Protein 
phosphorylation 
Figure 1.3 Model of signal transduction pathways of the FSH receptor. Upon binding of 
FSH to the FSH receptor, the Gsa subunit dissociates. In conjunction with GTP, this 
complex directly activates adenylyl cyclase, which produces cAMP from ATP. PKA is 
activated by cAMP, which leads to the dissociation of the catalytic subunit (C) from the 
regulatory subunit (R). The active catalytic site can activate proteins and transcription 
factors by phosphorylation. In addition, the production of cAMP leads to a rise in 
intracellular Ca2• via the gating of calcium channels 
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On stimulation by the occupied and activated receptor molecule, the G protein releases GDP and 
binds GTP. In its GTP-bound conformation, the activated G protein is capable of stimulating 
adenylyl cyclase. This active complex exhibits GTPase activity, and hydrolysis of the bound 
GTP to GDP terminates the action of the G protein. 
The activation of adenylyl cyclase by FSH and the subsequent synthesis of cAMP therefore 
triggers a cascade of events that ultimately lead to numerous physiological events in the target 
tissues including stimulation of granulosa cell proliferation, antrum formation, steroidogenesis, 
inhibin production, and accumulation ofplasminogen activator (Dahl and Hsueh, 1988). 
1.5.3 Receptor Desensitization 
In the absence of FSH, cultured granulosa cells rapidly lose FSH binding sites, but incubation in 
the presence of FSH also results in a dose- and time-dependent loss of receptors in a process 
referred to as down-regulation. Sertoli cells incubated in the presence of FSH exhibit a decrease 
in adenylyl cyclase sensitivity with a decrease of cAMP production preceding the FSH receptor 
loss. By modulating the number and functionality of FSH receptors, depending on the presence 
or absence ofFSH, target cells are able to protect themselves from overstimulation. 
In addition to an increase in phosphodiesterase activity and consequent cAMP degradation, an 
early event after receptor stimulation is agonist-induced receptor desensitization, due to 
uncoupling of the FSH receptor from Gs (Ford and LaBarbera, 1988). Uncoupling occurs through 
enzymatic phosphorylation of the C-terminal, intracellular domain of G protein-coupled 
receptors. 
As part of the desensitization process, FSH receptor numbers decrease through internalization of 
hormone-recep.tor complexes or reduced receptor protein synthesis. Receptor internalization is 
evident after 1-4 hours and precedes the decrease of receptor protein synthesis. Over longer 
periods of time, the presence of FSH results in a dose- and time-dependent decrease of functional 
FSH binding sites in porcine granulosa cells maintained in culture for up to 6 days (Simoni et al, 
1997). However, at the end of this period, levels ofFSH receptor mRNA increase. 
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1.6 Expression of FSH Receptor in Cell Lines 
The use of recombinant DNA technology led to major advances in the understanding of the 
structure of FSH receptors. Due to the similarity of cloned LH receptors and TSH receptors and 
the observation that all three glycoproteins act on their respective receptors via the cAMP 
pathway, it was assumed that the structural design of FSH receptors should also be similar to that 
of the other glycoprotein hormone receptors. Since Sertoli cells are a specific target of FSH 
action and do not bind LH, cDNA probes corresponding to selected regions of the LH receptor 
were used to screen a rat Sertoli cell cDNA library. The isolated cDNA were then transfected 
into human embryonic kidney cells, which then displayed an FSH-dependent and saturable 
increase in intracellular cAMP. In contrast, no cAMP stimulation was observed when using 
human (h) CG or hTSH, indicating the successful cloning of rat FSH receptor (Sprengel et al, 
1990). 
After cloning of the cDNA, the FSH receptors were expressed in a number of cell lines. Both rat 
and human receptor cDNA were successfully introduced into eukaryotic cell lines and shown to 
be functional, thus producing a numoer of recombinant lines useful for studying FSH receptor 
properties such as hormone binding, signal transduction, and desensitization. Thus, with the 
advent of FSH receptor cell lines the establishment of novel bioassays for FSH has been made 
possible. 
1.6.1 Assays for FSH 
The development of a detection and measurement system is a critical step in identifying 
hormones and understanding their functions. Generally, the first assays developed were 
performed in vivo, as functions that were possibly regulated by the hormone could be used as 
endpoints in assays to monitor the purification of that hormone. The major disadvantage of in 
vivo assays the lack of precision, as animal to animal variance is usually high. However, testing 
hormone preparations in live animals is extremely important in that their functions may be 
modified by unknown factors in vivo, which cannot be predicted by other methods. The standard 
in vivo assay for FSH is the ovarian augmentation test whereby rat ovaries are collected after FSH 
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treatment and their weights measured. Any increase in ovarian weight is presumed to be due to 
follicular development induced by FSH (Mannaerts et al, 1991). 
1.6.1.1 Radioimmunoassay vs. Bioassay 
The development of radioimmunoassays (RIA) for gonadotrophins has proved to be a valuable 
tool for understanding the role of these hormones in reproduction. The major components of an 
RIA are (1) an antibody that is specific for the hormone to be examined, (2) a radioactively 
labeled hormone, and (3) the unknown sample or standard. Through competitive binding of the 
labelled hormone and the hormone in the sample to the specific antibody, the amount of hormone 
in the unknown sample can be quantified. However, immunological activity may not always 
correlate with biological activity as antibodies generated against FSH may not recognize all 
isoforms equally and different antibodies may also recognize different isoforms preferentially. 
Despite these disadvantages, RIA's are usually far more sensitive than bioassays and do not 
require the use of animals for primary tissue culture. Therefore, both RIA and specific in vitro 
bioassays are required to further understand gonadotrophin potency and physiology (Ulloa-
Aguirre et al, 1995). 
Considering that neither receptor binding assays (RBA) nor RIAs measure postreceptor events, in 
vitro bioassays have been used to study the biopotency of FSH isoforms at the target cell level. 
These assays make use of culture systems involving either primary cell cultures or immortalized 
cell lines. One advantage of using in vitro bioassays compared to in vivo assays is that many 
more experimental tests can be performed per experimental animal, as only a small amount of 
tissue is normally required for each test. In addition, the precision of in vitro assays is usually 
much higher than in vivo assays (Mannaerts et al, 1991; Braileanu et al, 1998). 
To evaluate the potency of individual FSH isoforms, bioactivity and activities in either RIAs or 
receptor binding activity have been compared as the receptor-binding activity versus 
immunoactivity (RBA/RIA) or the bioactivity versus immunoactivity (B/1) ratio. In early studies, 
incubation of rat granulosa cells with equivalent concentrations of six different hamster FSH 
isoforms showed that the less acidic isoforms stimulated plasminogen activator release more than 
the highly acidic isoforms (Ulloa-Aguirre et al, 1988). 
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1.6.1.2 FSH in vitro Bioassays 
Numerous in vitro assays for FSH have been developed utilizing testicular tissue or granulosa cell 
preparations for binding assays. These include the stimulation of plasminogen activator in 
granulosa cells (Beers and Strickland, 1978) and estrogen production by Sertoli cells controlled 
by FSH sensitive aromatase (Padmanabhan et al, 1987). However, these assays are ethically 
costly, as large numbers of animals are required to provide tissue for primary cell culture. In 
addition, due to the requirements of primary cell cultures, disparities between cultures are 
difficult to avoid because of variation between individual animals. As a result, an acceptable 
level of sensitivity may be difficult to obtain in such bioassays. 
Recently, the development of a Chinese hamster ovary cell line that stably expresses the human 
FSH receptor has enabled the development of an FSH bioassay for human FSH (Albanese et al, 
1994). This bioassay effectively overcomes the main problems associated with more traditional 
in vitro bioassays, namely the ethical cost involved and sensitivity. Therefore, the feasibility of 
using this cell line for the development of an in vitro bioassay for ovine FSH will be examined in 
this study. 
Given the disadvantages of FSH bioassay systems requiring primary tissue culture, this study 
examines the use of an alternative bioassay system that does not suffer from the same drawbacks. 
Therefore, described in this study are preliminary experiments used to investigate the FSH 
stimulated cAMP response of a receptor cell line described by Albanese et al (Albanese et al, 
1994) followed by the validation of an in vitro FSH bioassay using ovine sera, purified ovine 
pituitary extracts, and pituitary cell culture media. The potential use of the bioassay as a tool for 
investigating heterogeneity in FSH is examined. 
